Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 11868 | 0.820 |
Why?
|
Carcinoma, Hepatocellular | 14 | 2024 | 2329 | 0.820 |
Why?
|
Liver Neoplasms | 16 | 2024 | 4353 | 0.760 |
Why?
|
Biliary Tract Neoplasms | 6 | 2023 | 186 | 0.750 |
Why?
|
Cholangiocarcinoma | 6 | 2024 | 578 | 0.720 |
Why?
|
Bile Duct Neoplasms | 6 | 2024 | 626 | 0.720 |
Why?
|
Organoplatinum Compounds | 7 | 2019 | 404 | 0.670 |
Why?
|
Pancreatic Neoplasms | 11 | 2024 | 5444 | 0.640 |
Why?
|
Stomach Neoplasms | 5 | 2024 | 1471 | 0.590 |
Why?
|
Fluorouracil | 6 | 2019 | 1648 | 0.590 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2024 | 220 | 0.560 |
Why?
|
Camptothecin | 3 | 2017 | 600 | 0.530 |
Why?
|
Adenocarcinoma | 7 | 2024 | 6364 | 0.450 |
Why?
|
Colorectal Neoplasms | 9 | 2024 | 6942 | 0.400 |
Why?
|
Gallbladder Neoplasms | 3 | 2023 | 189 | 0.390 |
Why?
|
Antineoplastic Agents | 13 | 2023 | 13648 | 0.370 |
Why?
|
Antibodies, Monoclonal | 12 | 2023 | 9249 | 0.320 |
Why?
|
Esophageal Neoplasms | 4 | 2024 | 1661 | 0.310 |
Why?
|
Protein Kinase Inhibitors | 7 | 2024 | 5696 | 0.280 |
Why?
|
Deoxycytidine | 7 | 2024 | 889 | 0.260 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2023 | 307 | 0.260 |
Why?
|
Dermatofibrosarcoma | 1 | 2006 | 50 | 0.260 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 961 | 0.260 |
Why?
|
Phenylurea Compounds | 4 | 2024 | 536 | 0.250 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2020 | 422 | 0.230 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2024 | 1758 | 0.230 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2822 | 0.220 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 90 | 0.200 |
Why?
|
Triazoles | 2 | 2020 | 897 | 0.190 |
Why?
|
Leucovorin | 3 | 2019 | 641 | 0.190 |
Why?
|
Biliary Tract | 1 | 2022 | 137 | 0.190 |
Why?
|
Esophagogastric Junction | 2 | 2024 | 351 | 0.180 |
Why?
|
Sirolimus | 4 | 2013 | 1545 | 0.180 |
Why?
|
Paclitaxel | 4 | 2024 | 1728 | 0.180 |
Why?
|
Carcinoid Tumor | 2 | 2013 | 225 | 0.170 |
Why?
|
Neutropenia | 2 | 2023 | 893 | 0.170 |
Why?
|
Anus Neoplasms | 1 | 2024 | 336 | 0.170 |
Why?
|
Gallstones | 1 | 2022 | 285 | 0.160 |
Why?
|
Cancer Care Facilities | 2 | 2014 | 426 | 0.160 |
Why?
|
ras Proteins | 3 | 2014 | 1053 | 0.160 |
Why?
|
SEER Program | 1 | 2024 | 1446 | 0.160 |
Why?
|
Albumins | 2 | 2023 | 577 | 0.160 |
Why?
|
Aged | 34 | 2024 | 171117 | 0.150 |
Why?
|
Rod Cell Outer Segment | 3 | 2001 | 50 | 0.150 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1028 | 0.150 |
Why?
|
Pigment Epithelium of Eye | 3 | 2001 | 209 | 0.150 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4893 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2423 | 0.140 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2593 | 0.140 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2020 | 1657 | 0.130 |
Why?
|
Neuroendocrine Tumors | 2 | 2013 | 654 | 0.130 |
Why?
|
Middle Aged | 33 | 2024 | 223009 | 0.130 |
Why?
|
Aged, 80 and over | 17 | 2024 | 59489 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2014 | 3537 | 0.130 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2045 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 4 | 2014 | 4520 | 0.120 |
Why?
|
Male | 37 | 2024 | 363698 | 0.110 |
Why?
|
Humans | 55 | 2024 | 765968 | 0.110 |
Why?
|
Cholecalciferol | 1 | 2019 | 550 | 0.110 |
Why?
|
Female | 38 | 2024 | 396112 | 0.110 |
Why?
|
Quinolines | 2 | 2024 | 769 | 0.110 |
Why?
|
Anilides | 1 | 2017 | 415 | 0.110 |
Why?
|
Pyridines | 2 | 2017 | 2888 | 0.110 |
Why?
|
Exercise Therapy | 1 | 2020 | 937 | 0.110 |
Why?
|
Glypicans | 1 | 2013 | 33 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 904 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1839 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1640 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 1761 | 0.090 |
Why?
|
Disease-Free Survival | 7 | 2017 | 6832 | 0.090 |
Why?
|
Adult | 24 | 2024 | 223044 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1630 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 754 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 660 | 0.090 |
Why?
|
Databases, Factual | 2 | 2018 | 8067 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 2 | 2010 | 2056 | 0.080 |
Why?
|
Quinazolines | 2 | 2013 | 1364 | 0.080 |
Why?
|
United States | 6 | 2024 | 72903 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4044 | 0.070 |
Why?
|
Catheter Ablation | 1 | 2021 | 2788 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Treatment Outcome | 13 | 2024 | 65188 | 0.070 |
Why?
|
Retrospective Studies | 8 | 2024 | 81514 | 0.070 |
Why?
|
Neoplasm Staging | 6 | 2024 | 11206 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1624 | 0.070 |
Why?
|
Withholding Treatment | 1 | 2011 | 621 | 0.070 |
Why?
|
Photoreceptor Cells | 1 | 1987 | 234 | 0.070 |
Why?
|
Skin Neoplasms | 1 | 2006 | 5849 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5337 | 0.070 |
Why?
|
Medicare | 1 | 2024 | 6823 | 0.070 |
Why?
|
Phagocytosis | 3 | 2001 | 1520 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2019 | 3425 | 0.060 |
Why?
|
Decision Making | 2 | 2017 | 3965 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3737 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1429 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2056 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8529 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 548 | 0.060 |
Why?
|
Retinal Degeneration | 2 | 2001 | 413 | 0.060 |
Why?
|
Cohort Studies | 4 | 2023 | 41649 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5719 | 0.060 |
Why?
|
Data Collection | 1 | 2013 | 3318 | 0.050 |
Why?
|
Estradiol | 1 | 2010 | 1947 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1119 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2018 | 4873 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2018 | 561 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 6499 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1611 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2024 | 639 | 0.050 |
Why?
|
Chemokine CXCL12 | 2 | 2017 | 455 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2023 | 330 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2024 | 0.040 |
Why?
|
Inflammation | 1 | 2020 | 10850 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3946 | 0.040 |
Why?
|
Survival Rate | 3 | 2020 | 12795 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 633 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4642 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 384 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 634 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2013 | 898 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2699 | 0.040 |
Why?
|
Gadolinium DTPA | 1 | 2023 | 823 | 0.040 |
Why?
|
Gene Amplification | 1 | 2024 | 1091 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2011 | 2531 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 419 | 0.040 |
Why?
|
Edema | 1 | 2023 | 760 | 0.040 |
Why?
|
Mutation | 3 | 2024 | 30198 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39193 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2887 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 618 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1731 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 816 | 0.040 |
Why?
|
Hyperbilirubinemia | 1 | 2017 | 74 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1801 | 0.030 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2017 | 147 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1857 | 0.030 |
Why?
|
Epistaxis | 1 | 2017 | 119 | 0.030 |
Why?
|
Intestinal Fistula | 1 | 2017 | 146 | 0.030 |
Why?
|
Carbachol | 1 | 1996 | 223 | 0.030 |
Why?
|
Angiopoietin-2 | 1 | 2017 | 187 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2485 | 0.030 |
Why?
|
Pancreas | 1 | 2022 | 1700 | 0.030 |
Why?
|
Prognosis | 3 | 2020 | 29922 | 0.030 |
Why?
|
Intestinal Perforation | 1 | 2017 | 253 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12437 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2570 | 0.030 |
Why?
|
Signal Transduction | 3 | 2013 | 23601 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1658 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54802 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6493 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2017 | 3222 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6547 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2017 | 3513 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 21056 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2054 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 561 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 163 | 0.030 |
Why?
|
Administration, Oral | 2 | 2011 | 4015 | 0.020 |
Why?
|
Quality of Life | 2 | 2024 | 13462 | 0.020 |
Why?
|
Hydroxyestrones | 1 | 2010 | 17 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2339 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 385 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10729 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12509 | 0.020 |
Why?
|
Somatostatin | 1 | 2012 | 459 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6309 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7202 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5329 | 0.020 |
Why?
|
Rats, Mutant Strains | 2 | 2001 | 59 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2210 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3850 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2010 | 410 | 0.020 |
Why?
|
Survival Analysis | 2 | 2011 | 10070 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1394 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14652 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3110 | 0.020 |
Why?
|
Cycloheximide | 1 | 1987 | 339 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 10383 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5929 | 0.020 |
Why?
|
Proteins | 1 | 2001 | 5995 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81819 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1987 | 2077 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1303 | 0.020 |
Why?
|
Animals | 5 | 2024 | 168764 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12056 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3272 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6203 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3111 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22332 | 0.010 |
Why?
|
Tumor Burden | 1 | 2010 | 1885 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3608 | 0.010 |
Why?
|
Piperidines | 1 | 2012 | 1664 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10429 | 0.010 |
Why?
|
Rats | 3 | 2001 | 23707 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59889 | 0.010 |
Why?
|
Temperature | 1 | 1987 | 2226 | 0.010 |
Why?
|
Rats, Long-Evans | 1 | 2001 | 380 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3596 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 36532 | 0.010 |
Why?
|
Kinetics | 1 | 1987 | 6274 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 1546 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4209 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2878 | 0.010 |
Why?
|
Time Factors | 2 | 2011 | 40065 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7562 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2009 | 2243 | 0.010 |
Why?
|
Palliative Care | 1 | 2014 | 3645 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1987 | 2817 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1996 | 18973 | 0.010 |
Why?
|
Hypertension | 1 | 2017 | 8626 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8611 | 0.010 |
Why?
|
Inositol 1,4,5-Trisphosphate | 1 | 1996 | 110 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3540 | 0.010 |
Why?
|
Lithium Chloride | 1 | 1996 | 82 | 0.010 |
Why?
|
Risk Factors | 1 | 2022 | 74840 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4562 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13632 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2001 | 1652 | 0.010 |
Why?
|
Blotting, Western | 1 | 2001 | 5020 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10808 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88835 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20659 | 0.000 |
Why?
|
Calcium | 1 | 2001 | 5767 | 0.000 |
Why?
|
Risk Assessment | 1 | 2009 | 24282 | 0.000 |
Why?
|